{"context":{"query":">>mondo>>clinical_trials","source_dataset":"mondo","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]MONDO:0002108,73,MONDO:0002108,160,-1]["},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"MONDO:0002108","source":"MONDO:0002108|thyroid cancer","targets":["NCT00604318|Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer|COMPLETED|PHASE4|INTERVENTIONAL","NCT01496313|To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer|COMPLETED|PHASE4|INTERVENTIONAL","NCT02946918|Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy|TERMINATED|PHASE4|INTERVENTIONAL","NCT03065218|99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) Patients|TERMINATED|PHASE4|INTERVENTIONAL","NCT03469310|Minimizing Narcotic Analgesics After Endocrine Surgery|COMPLETED|PHASE4|INTERVENTIONAL","NCT03969108|Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment|COMPLETED|PHASE4|INTERVENTIONAL","NCT06697782|Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer|COMPLETED|PHASE4|INTERVENTIONAL","NCT00410761|An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00435851|Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00704730|Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00794053|The Usefulness of Staining Lymph Nodes During Operations for Cancer Thyroid in Detecting the Nodes That Have Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00795782|Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT01083550|Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT01321554|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)|COMPLETED|PHASE3|INTERVENTIONAL","NCT01398085|IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients|ACTIVE_NOT_RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT01616316|Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT03570021|ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer|RECRUITING|PHASE3|INTERVENTIONAL","NCT04290663|Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up|RECRUITING|PHASE3|INTERVENTIONAL","NCT05468554|Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer|NOT_YET_RECRUITING|PHASE3|INTERVENTIONAL","NCT05999630|Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer|RECRUITING|PHASE3|INTERVENTIONAL","NCT06082180|A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer|RECRUITING|PHASE3|INTERVENTIONAL","NCT06554652|Selective Neck Dissection Versus Modified Neck Dissection in PTC|RECRUITING|PHASE3|INTERVENTIONAL","NCT06558981|Adjuvant Radiotherapy in High Risk Locally Advanced DTC|RECRUITING|PHASE3|INTERVENTIONAL","NCT06851663|Trop2-targeted immunoPET Imaging of Solid Tumors|RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT06860971|A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma|RECRUITING|PHASE3|INTERVENTIONAL","NCT00080574|The Effect of Thyroid Hormone on Drug Elimination in Cancer Patients|COMPLETED|PHASE2|INTERVENTIONAL","NCT00085293|Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131|COMPLETED|PHASE2|INTERVENTIONAL","NCT00095693|Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer|TERMINATED|PHASE2|INTERVENTIONAL","NCT00098345|Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT00098813|Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine|COMPLETED|PHASE2|INTERVENTIONAL","NCT00104871|Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy|COMPLETED|PHASE2|INTERVENTIONAL","NCT00115739|Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma|TERMINATED|PHASE2|INTERVENTIONAL","NCT00118248|Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT00121628|A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT00124527|Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT00126568|Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer|TERMINATED|PHASE2|INTERVENTIONAL","NCT00134043|Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT00176748|Treatment for Patients With Metastatic Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT00181168|Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT00251316|Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT00354523|Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma|TERMINATED|PHASE1/PHASE2|INTERVENTIONAL","NCT00358956|A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT00519896|Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT00784303|Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology|COMPLETED|PHASE2|INTERVENTIONAL","NCT00786552|Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer|UNKNOWN|PHASE2|INTERVENTIONAL","NCT00804830|Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer|TERMINATED|PHASE2|INTERVENTIONAL","NCT00887107|Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma|COMPLETED|PHASE2|INTERVENTIONAL","NCT00896454|Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium|COMPLETED|PHASE2|INTERVENTIONAL","NCT00936858|RAD001 for Patients With Radioiodine Refractory Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT00948337|A Study With Health Educational Material on Health Promotion in Cancer Survivors|UNKNOWN|PHASE2|INTERVENTIONAL","NCT01025453|Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT01141309|Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT01173289|Study of External Beam Radiotherapy to Thyroid Carcinoma|COMPLETED|PHASE2|INTERVENTIONAL","NCT01270321|Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT01396733|Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer|WITHDRAWN|PHASE2|INTERVENTIONAL","NCT01502410|Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT01709292|Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT01723202|Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT01728623|A Study of E7080 in Subjects With Advanced Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT01830504|A Multicenter Phase II Pilot Open Label|UNKNOWN|PHASE2|INTERVENTIONAL","NCT01882816|Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT01964144|An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT01994200|Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients|WITHDRAWN|PHASE1/PHASE2|INTERVENTIONAL","NCT02084732|Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study|COMPLETED|PHASE2|INTERVENTIONAL","NCT02152137|Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT02244463|A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT02383927|Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations|COMPLETED|PHASE2|INTERVENTIONAL","NCT02390739|Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer|WITHDRAWN|PHASE1/PHASE2|INTERVENTIONAL","NCT02390934|Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT02408887|Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer|TERMINATED|PHASE2|INTERVENTIONAL","NCT02472080|Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study|TERMINATED|PHASE2|INTERVENTIONAL","NCT02515084|Comparison DW-MRI vs FDG PET/CT in the Detection of Early Recurrence of Cervical Well-differentiated Thyroid Carcinoma|COMPLETED|PHASE2|INTERVENTIONAL","NCT02628067|Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT02657551|A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT02702388|A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile|COMPLETED|PHASE2|INTERVENTIONAL","NCT02731352|Study of Apatinib in Patients With Differentiated Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT02947035|Molecular Testing to Direct Extent of Initial Thyroid Surgery|COMPLETED|PHASE2|INTERVENTIONAL","NCT02988817|Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT03099356|Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer|RECRUITING|PHASE2|INTERVENTIONAL","NCT03109847|Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers|TERMINATED|PHASE2|INTERVENTIONAL","NCT03127098|QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer|TERMINATED|PHASE1/PHASE2|INTERVENTIONAL","NCT03139747|UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone|SUSPENDED|PHASE2|INTERVENTIONAL","NCT03175224|APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors|RECRUITING|PHASE2|INTERVENTIONAL","NCT03246958|Nivolumab Plus Ipilimumab in Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT03300765|Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer|UNKNOWN|PHASE2|INTERVENTIONAL","NCT03360890|Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT03475953|A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors|UNKNOWN|PHASE1/PHASE2|INTERVENTIONAL","NCT03630120|Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer|TERMINATED|PHASE2|INTERVENTIONAL","NCT03732495|Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas|UNKNOWN|PHASE2|INTERVENTIONAL","NCT03753919|Durvalumab Plus Tremelimumab for the Treatment of Patients with Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial|TERMINATED|PHASE2|INTERVENTIONAL","NCT03841617|The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer|RECRUITING|PHASE2|INTERVENTIONAL","NCT04115514|Treatment of ARDS With Instilled T3|RECRUITING|PHASE2|INTERVENTIONAL","NCT04136912|3-D Super Resolution Ultrasound Microvascular Imaging|TERMINATED|PHASE2|INTERVENTIONAL","NCT04180007|Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers|UNKNOWN|PHASE2|INTERVENTIONAL","NCT04238624|Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT04309136|Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer|UNKNOWN|PHASE2|INTERVENTIONAL","NCT04521348|Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT04524884|Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study|UNKNOWN|PHASE2|INTERVENTIONAL","NCT04544111|PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT04552769|Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer|COMPLETED|PHASE2|INTERVENTIONAL"]}]}